




**Dr. Sudha Bhattacharya**  
**World Without GNE Myopathy**



## **GNEM SYMPOSIUM SPEAKER SERIES**

*presented by The Neuromuscular Disease Foundation*

# **Potential Therapeutic Options For GNE Myopathy: Lessons From Other Muscle Diseases**

Sunday, August 28th 2022 • 9am PT

- 1- GNE myopathy is a rare genetic disorder that causes muscle wasting due to mutations in the GNE gene.
- 2- Current efforts to bring treatments for GNE myopathy are centered around gene delivery using AAV vector, and supplementation with the sialic acid precursor, N-acetyl-D-mannosamine (ManNAc). These are our most promising options at present.
- 3- Other therapeutic options, like the use of cell-based therapies to regenerate muscle tissue, or delivery of mRNA (in place of DNA ) to the muscles are being tried for Duchene muscular dystrophy (DMD), a more commonly occurring genetic disease.
- 4- It is prudent to keep track of these developments as some of these could prove beneficial for GNE myopathy as well.





## GNEM SYMPOSIUM SPEAKER SERIES

*presented by The Neuromuscular Disease Foundation*

Speaker Series #082822

**Dr. Sudha Bhattacharya, World Without GNE Myopathy**

FINAL HIGHLIGHTS:

**“Potential Therapeutic Options For GNE Myopathy: Lessons From Other Muscle Diseases”**

### Key Takeaways

- Many technological innovations are in the pipeline for muscle diseases
- Each technology has its advantages and limitations
- Cell-based therapies are giving promising results for DMD and LGMD, but clinical data is still small
- mRNA-based therapies are rapidly progressing and, once developed for DMD, could be simple to adapt to GNEM

